{"id":"W1979370923","doi":"10.1016/j.breast.2007.12.004","title":"Fulvestrant: Expanding the endocrine treatment options for patients with hormone receptor-positive advanced breast cancer","year":2008,"lang":"en","type":"review","venue":"The Breast","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"AstraZeneca","keywords":"Fulvestrant; Exemestane; Medicine; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Tolerability; Anastrozole; Clinical trial; Tamoxifen; Cancer; Aromatase inhibitor; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004897211,0.000523778,0.0005974752,0.00003654922,0.0004931681,0.00002898118,0.0003158162,0.000195416,0.000008416181],"category_scores_gemma":[0.000004840716,0.0002316205,0.0004351924,0.0001528101,0.0002007282,0.000006077315,0.00006433397,0.0002037688,0.00001243109],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000116626,"about_ca_system_score_gemma":0.0002077909,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003839322,"about_ca_topic_score_gemma":0.000006658898,"domain_scores_codex":[0.9985607,0.0001455466,0.0002756891,0.0004534315,0.0001466634,0.0004180286],"domain_scores_gemma":[0.9989591,0.00007055714,0.0002567235,0.0005057072,0.0001113843,0.00009651439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006316147,0.0003114466,0.00002028998,0.0002187948,0.001564616,0.000004201334,0.00007516977,0.000024572,0.0002776152,0.00003046324,0.0008425994,0.9959986],"study_design_scores_gemma":[0.004755191,0.00255033,0.0007083242,0.00328037,0.002715576,0.002800026,0.0000725746,0.000003888751,0.000392965,0.000005815627,0.9815508,0.001164214],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00354004,0.9905394,0.00003353135,0.0001480769,0.0001519006,0.002539967,0.002912632,0.00002060293,0.000113848],"genre_scores_gemma":[0.002577055,0.9929611,0.00007323349,0.0000207751,0.0004462008,0.001316549,0.001986975,0.0000887487,0.0005293804],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9948344,"threshold_uncertainty_score":0.9445211,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00941036389523718,"score_gpt":0.2777189603102916,"score_spread":0.2683085964150544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}